| INDICATION'S | "Drug developers should know that if their compound is failing because of a CYP 3A degradation problem, our boosting strategy might present a second chance to market." "We would never expect drugs to be designed with boosting in mind, but if they run into this problem, then having a second chance is enormously beneficial." |
| UPDATE | 06.03 |
| COMPANY | This data is not available for free |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |